View the slide viewer

Have questions about this assay kit?

Human INSRb Reporter Assay Kit

1 x-96 well format assays
1 x-384 well format assays
1 x-96 well format assays
1 x-384 well format assays

Product Description and Product Data

This is an all-inclusive cell-based luciferase reporter assay kit for the Human Insulin Receptor, isoform B (INSRb). INDIGO’s INSRb reporter assay utilizes proprietary mammalian cells that have been engineered to provide constitutive expression of INSRb. In addition to INSRb Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user’s test samples, a reference activator, Luciferase Detection Reagent, and a cell culture-ready assay plate. The principal application of this assay is in the screening of test samples to quantify any functional activity, either activating or inhibitory, that they may exert against human INSRb or the coupled RAS-MAPK pathway. This kit provides researchers with clear, reproducible results, exceptional cell viability post-thaw, and consistent results lot to lot. Kits must be stored at -80C. Do not store in liquid nitrogen. Note: reporter cells cannot be refrozen or maintained in extended culture.


  • Ready to Use Upon Receipt

  • Includes All Needed Components
  • Contains Transfected Reporter Cells
  • Eliminates Cell Licensing Fees
  • Clear, Reproducible Results
  • Consistent Results Lot to Lot

Product Specifications

Target TypeGrowth Factor Receptor
Receptor FormNative
Assay ModeAntagonist
Kit Components
  • INSRb Reporter Cells
  • Cell Recovery Medium (CRM)
  • Compound Screening Medium (CSM)
  • Insulin, (ref. activator; in PBS/0.1% BSA )
  • Detection Substrate
  • Detection Buffer
  • White, sterile, cell-culture ready assay plate
Shelf Life6 months
Orthologs AvailableNo
Shipping RequirementsDry Ice
Storage temperature-80C


Activation dose-response assays were performed according to the protocol provided in this Technical Manual. 200 μl / well of INSRb Reporter Cell suspension was dispensed into the 96-well assay plate, which was then incubated for 4 hours. The concentrated stock of Insulin (provided), IGF-I and IGF-II (Peprotech) were further diluted using CSM to produce treatment media at the desired assay concentrations. The pre-culture media were discarded from the assay wells and 200 μl per well of the prepared treatment media were dispensed (n = 3/conc.), including ‘untreated’ control wells. Following 22-hours incubation the treatment media were discarded, Luciferase Detection Reagent was added, and luminescence intensity per well was quantified. Values of average relative light units (RLU) and corresponding values of standard deviation (SD), percent coefficient of variation (%CV), Fold-Activation and Z’ were determined for each treatment concentration. GraphPad Prism software was used to perform the least-squares method of non-linear regression to plot Fold Activation vs. Log10[ng/mL] and determinate EC50 values.
INSRb reporter cells were co-treated with an EC80 concentration of the reference activator Insulin (provided) and varying concentrations of the small molecule INSRb inhibitors BMS-754807, Linsitinib, and BMS-536924 (all compounds obtained from Cayman Chemical, Ann Arbor MI, USA). The range of determined IC50 values is shown; (n = 3 / conc.). INDIGO’s Live Cell Multiplex (LCM) Assay was performed and confirmed that no treatment concentrations were cytotoxic (data not shown). Non-linear regression analyses of RLU vs. Log10[Inhibitor, nM] were plotted and IC50 determinations made using GraphPad Prism software.

Target Background

Insulin Receptor is a glycosylated, disulfide-linked α2β2 tetramer that belongs to a subfamily of receptor tyrosine kinases, including insulin-like growth factor 1 receptor (IGF-1R) and insulin-receptor-related receptor (IRR). Two isoforms of the insulin receptor are known, the full-length INSRb and the smaller INSRa, which is the product of splice variation that excludes exon 112. Reporter cells expressing the larger INSRb are provided in this assay kit. The two insulin receptor isoforms derive from respective precursor proteins which have been processed by a furin-like protease to produce an α/β subunit complex. The α/β subunits then undergo disulfide linkage to form a mature, functional tetrameric receptor. Insulin receptors exist as both homodimers and heterodimers of each isoform. In addition, receptor hybrids of INSRb and IGF-1R have been characterized. Insulin is a 5.73 kD non-glycosylated globular protein that is the predominant physiological ligand of the insulin receptors3. It is produced by beta cells of the pancreatic islets, and it is considered one of the main anabolic hormones of the body. Insulin binds to and activates the insulin receptor, promoting the absorption of glucose from the blood into the liver, fat, and skeletal muscle cells. Type 1 diabetes (T1D) can arise when pancreatic cells lose the ability to produce insulin. The consequence is a damaging build-up of sugars in the bloodstream. Activation of the insulin receptor also controls transcription of metabolic genes that contribute to cellular growth and differentiation. However, dysregulation of insulin-mediated signaling is linked to many human diseases, such as type 2 diabetes (T2D) and cancers. Consequently, the insulin receptor and its associated receptors command considerable interest in therapeutics development and drug safety screening.

INDIGO’s INSRb Reporter Cells express a hybrid Elk-1 transprion factor in which the native Elk-1 DNA-binding domain (DBD) has been replaced with the yeast Gal4 DBD sequence. The luciferase reporter gene is functionally linked to an upstream Gal4 Upstream Activation Sequence (UAS). When activated, Elk-1 binds to the UAS elements to initiate the formation of a complete transcription complex that drives Luciferase gene expression. Quantifying changes in luciferase activity in the treated reporter cells relative to the untreated cells provides a sensitive, dose-dependent surrogate measure of drug-induced changes in INSRb activity.

Therefore, the principal application of this assay is in the screening of test materials to quantify any functional interactions, either activating or inhibitory, that they may exert against INSRb or the coupled RAS-MAPK pathway.

Also available as a service

Insulin Receptor, isoform B

Have questions about this assay kit?